About OmerosPipelineInvestorsNews

Investor Relations Home

Due to an error by our third-party webcasting provider, the live webcast on August 9 was disconnected for approximately three minutes during the Q&A segment. However, the complete webcast is available for replay on demand.

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.55 (5.21%)
Data as of 12/06/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
12/06/16Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment
-- 15 Year-Old with Stem Cell Transplant-Associated TMA Had Previously Developed Additional Life-Threatening Condition while on Soliris® -- SEATTLE--(BUSINESS WIRE)--Dec. 6, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who is currently receivin... 
 Printer Friendly Version
12/05/16Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy
-- Small-Molecule Inhibitors Enhance Immune System and May Offer Advantages over Existing Cancer Therapies -- SEATTLE--(BUSINESS WIRE)--Dec. 5, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to cancers, substantially and statistically significantly boost levels of cytokines and reduce the popula... 
 Printer Friendly Version
11/30/16International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury
-- NEURON-Funded Program Will Evaluate Benefits of Omeros’ MASP-2 Antibody -- SEATTLE--(BUSINESS WIRE)--Nov. 30, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded €1.3 million in grant funding to study the benefits of inhibiting mannan-binding lectin-associated serine protease-2 (MASP-2) and the lectin pathway in trau... 
 Printer Friendly Version
11/21/16Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial
-- Six-Month Extension of Patent Exclusivity and Label Expansion Expected -- SEATTLE--(BUSINESS WIRE)--Nov. 21, 2016-- Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% in pediatric patients undergoing cataract surgery. OMIDRIA is approved by the FDA for use in adult patients undergoing cata... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2015 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.